BridgeMD
Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
EU CTIS ID: 2025-524720-22-00
What this study is testing
To evaluate whether intraglandular application of botulinum toxin type A prior to radiotherapy preserves salivary gland function.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Histologically confirmed head and neck squamous cell carcinoma indicated for radiotherapy
- Symmetrical function of submandibular glands on pre-treatment Tc99m scintigraphy
- Signed informed consent
You likely can't join if
- Previous radiotherapy to the head and neck region
- Known salivary gland disease (e.g., sialolithiasis, recurrent sialadenitis)
- Pregnancy or lactation
- Known allergy to botulinum toxin or neuromuscular transmission disorders
- Prior surgery affecting major salivary glands (to be evaluated individually)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.